ATHE Alterity Therapeutics Limited - American Depositary Shares
ATHE Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
ATHE Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
ATHE Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
- Strong Buy 1 20.0%
- Buy 3 60.0%
- Hold 1 20.0%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
4 analysts · 2026-08-16Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ATHE | — | — | — | — | — | — |
| KZIA | — | — | — | — | — | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 24 filers · $1.7M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 7 (+7 vs prior Q) | 0 (-2 vs prior Q) | 6 (+4 vs prior Q) | 0 (-4 vs prior Q) | +69K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Twin Lakes Capital Management, LLC | $747,815 | 139,258 | 44.57% | Shares |
| GREENLEAF TRUST | $332,940 | 62,000 | 19.85% | Shares |
| HB Wealth Management, LLC | $313,930 | 58,460 | 18.71% | Shares |
| CITADEL ADVISORS LLC | $201,896 | 37,597 | 12.03% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $54,983 | 10,239 | 3.28% | Shares |
| GAMMA Investing LLC | $12,399 | 2,309 | 0.74% | Shares |
| RHUMBLINE ADVISERS | $10,786 | 2,009 | 0.64% | Shares |
| Providence Capital Advisors, LLC | $1,074 | 200 | 0.06% | Shares |
| Integrated Wealth Concepts LLC | $392 | 73 | 0.02% | Shares |
| OSAIC HOLDINGS, INC. | $362 | 68 | 0.02% | Shares |
| MORGAN STANLEY | $269 | 50 | 0.02% | Shares |
| Blue Trust, Inc. | $215 | 40 | 0.01% | Shares |
| Farther Finance Advisors, LLC | $205 | 39 | 0.01% | Shares |
| CoreCap Advisors, LLC | $113 | 21 | 0.01% | Shares |
| Sugarloaf Wealth Management, LLC | $109 | 33 | 0.01% | Shares |
| HRT FINANCIAL LP | $92 | 17,292 | 0.01% | Shares |
| Steward Partners Investment Advisory, LLC | $32 | 6 | 0.00% | Shares |
| UBS Group AG | $27 | 5 | 0.00% | Shares |
| ACADIAN ASSET MANAGEMENT LLC | $10 | 1,863 | 0.00% | Shares |
| Cranbrook Wealth Management, LLC | $6 | 1 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $5 | 1 | 0.00% | Shares |
| DANSKE BANK A/S | $5 | 1 | 0.00% | Shares |
| CITIGROUP INC | $5 | 1 | 0.00% | Shares |
| Motiv8 Investments LLC | $0 | 40 | 0.00% | Shares |
Company insiders 2 insiders · 0 officers · 2 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Julian Michael Babarczy | Director | June 15, 2026 A | — | 0 | 0 | $0 |
| Lawrence Bernard Gozlan | Director | June 15, 2026 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Life Biosciences LLC ×12 filings | Oct. 31, 2022 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.